logo-loader
RNS
viewReNeuron Group PLC

ReNeuron Group plc - Notification of Interim Results

RNS Number : 6598T
ReNeuron Group plc
18 November 2019
 

 

 

18 November 2019

   AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Notification of Interim Results

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2019 on Friday 6 December 2019.

 

A meeting for analysts will be held at 09.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

 

To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 09.30am on the day of the results:

 

https://webcasting.buchanan.uk.com/broadcast/5dcc32879535b1405a05b0bd 

 

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

 

                                                                        ENDS

 

Contacts:

 

ReNeuron

 

 

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

 

Buchanan (UK Media/Investor Relations)

 

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham

 

Argot Partners (US Media/Investor Relations)

Claudia Styslinger, David Rosen

 

+1 212 600 1902

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

 

 

N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Mia Gardner

 

+44 (0) 20 7496 3000

 

 

 

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOREANFXFDANFFF

Quick facts: ReNeuron Group PLC

Price: 109

Market: LSE
Market Cap: £34.7 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18